Oramed Pharmaceuticals Inc. (ORMP)

Oramed Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Aug 31, 2021	Aug 31, 2020	Aug 31, 2019
Cash & Equivalents	18.58	9.06	40.46	77.25	19.3	3.33
Short-Term Investments	158.02	152.99	115.26	16.9	20.6	28.95
Cash & Cash Equivalents	176.59	162.05	155.72	94.14	39.9	32.28
Cash Growth	14.87%	4.06%	65.41%	135.94%	23.60%	5.97%
Other Current Assets	0.5	0.54	1.39	1.2	0.61	1.04
Total Current Assets	177.1	162.58	157.11	95.34	40.51	33.32
Property, Plant & Equipment	1.43	1.57	1.8	0.93	0.17	0.02
Long-Term Investments	25.1	56.37	2.71	31.71	3.93	1.3
Other Long-Term Assets	0.03	0.03	0.02	0.02	0.02	0.02
Total Long-Term Assets	26.56	57.97	4.53	32.66	4.12	1.34
Total Assets	203.65	220.55	161.64	128	44.63	34.66
Accounts Payable	1.27	1.93	4.16	3.85	1.7	2.54
Deferred Revenue	4	4	5.34	6.95	9.65	12.36
Current Debt	32.29	51.28	0.25	0.13	0.04	0
Other Current Liabilities	-4	-4	-4	-4.24	-6.86	-9.59
Total Current Liabilities	33.56	53.21	5.75	6.68	4.54	5.31
Long-Term Debt	0.27	0.34	0.65	0.4	0.03	0
Other Long-Term Liabilities	4.1	4.1	4.09	4.4	7.19	9.96
Total Long-Term Liabilities	4.38	4.44	4.74	4.8	7.22	9.96
Total Liabilities	37.93	57.66	10.49	11.48	11.75	15.27
Total Debt	32.56	51.62	0.89	0.53	0.08	0
Debt Growth	3939.70%	5674.27%	67.73%	610.67%	-	-
Retained Earnings	-156.02	-157.56	-163.08	-114.85	-92.61	-81.1
Shareholders' Equity	166.64	163.82	151.81	115.77	32.88	19.39
Net Cash / Debt	144.03	110.43	154.83	93.61	39.83	32.28
Net Cash / Debt Growth	-5.82%	-28.68%	65.40%	135.05%	23.37%	5.97%
Net Cash Per Share	3.47	2.72	3.97	3.29	1.94	1.85
Working Capital	143.54	109.37	151.36	88.66	35.98	28.02
Book Value Per Share	4.08	4.06	3.89	4.07	1.60	1.11

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).